Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study

Vucic S.; Coles A. J.; Arnold D. L.; Hartung H-P; Havrdova E.; Selmaj K. W.; Margolin D. H.; Palmer J.; Oyuela P.; Panzara M. A.; Compston D. A. S.

首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study

【24h】

Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study

机译：Alemtuzumab在先前治疗后复发的复发缓解型MS患者中的疗效和安全性：CARE-MS II研究的四年随访

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Multiple sclerosis: clinical and laboratory research》 |2015年第6期|共1页
作者
Vucic S.; Coles A. J.; Arnold D. L.; Hartung H-P; Havrdova E.; Selmaj K. W.; Margolin D. H.; Palmer J.; Oyuela P.; Panzara M. A.; Compston D. A. S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study [J] . Vucic S., Coles A. J., Arnold D. L., Multiple sclerosis: clinical and laboratory research . 2015,第6期

机译：Alemtuzumab在先前治疗后复发的复发缓解型MS患者中的疗效和安全性：CARE-MS II研究的四年随访
2. Patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy demonstrate durable improvements in clinical outcomes with alemtuzumab-5-year follow-up of CARE-MS II [J] . Alroughani Raed, Al Jumah Mohamed, Arnold Douglas L., Multiple sclerosis: clinical and laboratory research . 2016,第6期

机译：活动性缓解型多发性硬化症患者以及对先前治疗反应不足的患者通过Alemtuzumab对CARE-MS II进行了5年的随访，证明了其临床疗效的持久改善
3. Efficacy of Alemtuzumab Is Durable Over 6 Years in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) [J] . Broadley S., Alroughani R., Brassat D., Multiple sclerosis: clinical and laboratory research . 2017,第2期

机译：在没有连续治疗的情况下，患有活性复发的多发性硬化和对前治疗的患者的患者持续6年患者耐久性超过6年的疗效（Care-MS II）
4. Brain White Matter Pathological Comparison in MS Relapsing-Remitting Patients, Clinically Isolated Syndrome Patients and Normal Subjects Using Quantitative Magnetization Transfer Imaging [C] . N. Riyahi-Alam, K. Pahlavan, M.H. Harirchian, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：使用定量磁化转移成像技术的MS复发型患者，临床孤立综合征患者和正常受试者的脑白质病理学比较
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study) [O] . Annette F. Okai, Lilyana Amezcua, Regina R. Berkovich, 2019

机译：非洲人复发-多发性硬化症患者中Alemtuzumab的疗效和安全性：CARE-MS I和II的8年随访（TOPAZ研究）
7. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study [O] . Tjalf Ziemssen, Ann D. Bass, Regina Berkovich, 2020

机译：Alemtuzumab在高活跃疾病患者中通过9年通过9年的疗效和安全性：POSE-MS I和II患者在TOPAZ推广研究中的疗效分析

Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study

著录项

相似文献

相关主题

期刊订阅